Kiniksa Pharmaceuticals Ltd (KNSA)

NASDAQ
14.50
+0.35(+2.47%)
  • Volume:
    660,529
  • Bid/Ask:
    14.37/15.00
  • Day's Range:
    14.08 - 14.62

KNSA Overview

Prev. Close
14.15
Day's Range
14.08-14.62
Revenue
-
Open
14.23
52 wk Range
13.01-24.65
EPS
-2.82
Volume
660,529
Market Cap
990.81M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
-
P/E Ratio
-
Beta
-
1-Year Change
-27.61%
Shares Outstanding
68,332,034
Next Earnings Date
Aug 03, 2021
What is your sentiment on Kiniksa Pharmaceuticals Ltd?
or
Market is currently closed. Voting is open during market hours.

Kiniksa Pharmaceuticals Ltd News

Kiniksa Pharmaceuticals Ltd Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyStrong BuyStrong BuyBuySell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell

Kiniksa Pharmaceuticals Ltd Company Profile

Kiniksa Pharmaceuticals Ltd Company Profile

Employees
168

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company’s preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Read More
  • I'm surprised no activity there is little activity on this stock.
    0
    • The FDA has approved. - ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis- Commercial launch expected in April 2021- Kiniksa launches Kiniksa One Connect™ patient support program
      0
      • Breakthrough Therapy designation granted by the FDA for rilonacept for the treatment of recurrent pericarditis, due date is 21st March 2021 under priority review.That should help some movement
        0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.